Disease · MONDO_0000450
secondary progressive multiple sclerosis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. secondary progressive multiple sclerosis. Diseases, record MONDO_0000450. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000450
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs8
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SIPONIMOD FUMARIC ACID | CHEMBL4298150 | Small molecule | Approval | PMDA | 2 | 0 | 0 | Drugs and targets |
| OFATUMUMAB | CHEMBL1201836 | Antibody | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| FREXALIMAB | CHEMBL5095122 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TERIFLUNOMIDE | CHEMBL973 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALDESLEUKIN | CHEMBL1201438 | Protein | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OCRELIZUMAB | CHEMBL2108041 | Antibody | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CLADRIBINE | CHEMBL1619 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SIPONIMOD | CHEMBL2336071 | Small molecule | Unknown | USAN | 1 | 0 | 0 | Drugs and targets |
Targets6
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| MS4A1 | B-lymphocyte antigen CD20 | 2 | B-lymphocyte antigen CD20 binding agent | Approval | https://conductscience.org/library/genes/931 | Drugs and targets |
| S1PR1 | Sphingosine 1-phosphate receptor 1 | 2 | Sphingosine 1-phosphate receptor Edg-1 agonist | Approval | https://conductscience.org/library/genes/1901 | Drugs and targets |
| DHODH | Dihydroorotate dehydrogenase (quinone), mitochondrial | 1 | Dihydroorotate dehydrogenase inhibitor | Phase 2 | https://conductscience.org/library/genes/1723 | Drugs and targets |
| IL2RA | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 1 | https://conductscience.org/library/genes/3559 | Drugs and targets |
| IL2RB | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 1 | https://conductscience.org/library/genes/3560 | Drugs and targets |
| IL2RG | Interleukin-2 receptor | 1 | Interleukin-2 receptor agonist | Phase 1 | https://conductscience.org/library/genes/3561 | Drugs and targets |
Trials4
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03933202 | A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) | 291 | 2026-01-02 | Multiple Sclerosis | CLADRIBINE | Its record names the disease | ClinicalTrials.gov | |
| NCT06141486 | Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis | Phase 3 | 943 | Multiple Sclerosis | FREXALIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01487096 | Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses | Phase 2 | 179 | Multiple Sclerosis | TERIFLUNOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT06677710 | IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis | Phase 1 | 34 | Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS) | ALDESLEUKIN, OCRELIZUMAB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cladribine Tablets: Switch From Oral vs Cladribine Tablets: Switch From Infusion: Number of Participants With At Least One Concomitant Medication | 98 of 103 | 73 of 85 | 188 | NCT03933202 | Trial comparisons |
| Cladribine Tablets: Switch From Oral vs Cladribine Tablets: Switch From Infusion: deaths from any cause | 2 of 103 | 0 of 85 | 188 | NCT03933202 | Trial comparisons |
| Cladribine Tablets: Switch From Oral vs Cladribine Tablets: Switch From Infusion: serious adverse events | 10 of 103 | 14 of 85 | 188 | NCT03933202 | Trial comparisons |
Papers from its trials3
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0000450
GET https://conductscience.org/api/diseases/v1/MONDO_0000450/drugs